GlassScriptPhysician profile
Allison J Johnson
NPI 1881196319
$3,301.28
in general payments reported to CMS, 2019-2025
27 companies · $833 in 2025
The $833 reported for 2025 was more than what 84% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $96.67 · 2022: $285 · 2023: $1,095 · 2024: $992 · 2025: $833.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,920.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,919.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $609.61 | 2022-2025 | Mounjaro, Zepbound, Basaglar |
| Amgen INC. | $550.72 | 2023-2025 | Evenity, Prolia, Prolia |
| Pfizer INC. | $352.05 | 2022-2025 | |
| Novo Nordisk INC | $321.14 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Astellas Pharma US INC | $286.30 | 2023-2025 | Veozah, Myrbetriq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $144.11 | 2023-2025 | Jardiance |
| Daiichi Sankyo INC. | $140.17 | 2022-2024 | Injectafer |
| Novartis Pharmaceuticals Corporation | $108.20 | 2024-2025 | |
| Vertex Pharmaceuticals Incorporated | $94.85 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $90.91 | 2023-2025 | Eliquis, Camzyos |
| Janssen Pharmaceuticals, INC | $84.16 | 2021-2023 | Xarelto |
| Exact Sciences Corporation | $81.21 | 2023-2024 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $60.99 | 2023-2025 | Trelegy Ellipta, Arexvy |
| Sanofi-Aventis U.S. LLC | $53.90 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $48.82 | 2023-2024 | Farxiga |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $47.62 | 2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $33.96 | 2022 | |
| Boston Scientific Corporation | $30.86 | 2024 | Watchman Flx |
| Mylan Specialty L.P. | $22.89 | 2022 | |
| Medtronic, INC. | $22.04 | 2024 | Minimed 780g |
| Inspire Medical Systems, INC. | $19.52 | 2025 | Inspire |
| Alkermes, INC. | $19.12 | 2025 | Aristada, Lybalvi |
| Dexcom, INC. | $18.31 | 2025 | Dexcom G6 Transmitter |
| Axonics, INC. | $17.71 | 2024 | Axonics |
| Merck Sharp & Dohme LLC | $14.90 | 2025 | Capvaxive, Gardasil 9, Vaxneuvance |
| Actelion Pharmaceuticals US, INC. | $13.62 | 2025 | Opsumit, Uptravi |
| Solventum Corporation | $13.59 | 2024 | V.A.C.Ulta, Prevena, V.A.C. Dermatac |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allison Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.